DR.WU SKINCARE announced its third-quarter financial results on the 14th, reporting a significant improvement in profitability driven by a sharp rebound in non-operating income. Net profit after tax reached NT$111 million for the quarter, up 15.6% year-on-year, and successfully turned profitable from a loss in the second quarter. Earnings per share (EPS) for the quarter came in at NT$2.47.
The board of directors also approved a cash dividend of NT$4 per share for the quarter, making DR.WU SKINCARE one of the few biotech companies to distribute dividends for consecutive quarters. Cumulative cash dividends distributed over the first three quarters of this year have reached NT$8 per share. Based on the previous day’s closing price of NT$118, the implied cash dividend yield stands at 6.7%.
Third-quarter revenue totaled NT$321 million, up 5.6% year-on-year. Operating profit reached NT$110 million, down 3.5% from a year earlier. Non-operating income surged to NT$21.49 million, a 29-fold increase year-on-year, mainly reflecting contributions from interest income and foreign exchange valuation gains. Net profit after tax amounted to NT$111 million, up 15.6%, with quarterly EPS of NT$2.47. Cumulative revenue for the first three quarters reached NT$893 million, up 0.67% year-on-year, while net profit after tax totaled NT$263 million, down 21.7%, with EPS of NT$5.84. The decline was primarily attributable to foreign exchange valuation losses recognized in the second quarter, which resulted in a quarterly loss.
The board also approved dividend distribution and cash payouts from capital surplus, with a total distribution of NT$4 per share for the quarter, representing a generous payout policy. Of this amount, NT$2 per share will be distributed as cash dividends and NT$2 per share from capital surplus. Based on quarterly EPS of NT$2.47, the payout ratio reaches 161.9%.
Previously, DR.WU SKINCARE distributed NT$2 per share in cash dividends in the second quarter, bringing total dividends for the first half of the year to NT$4 per share. Including the third-quarter distribution, cumulative dividends for the first three quarters have reached NT$8 per share.
Looking ahead to the fourth quarter, the company stated that it is targeting major year-end shopping festivals such as Singles’ Day (11.11) and Double 12 by partnering with distribution channels to roll out a series of promotional campaigns to stimulate festive demand. In addition, the “DR.WU Beauty Shot Dual Collagen Peptide Drink,” featuring an innovative “tablet plus drink” dual-effect beauty supplementation concept, officially launched in September. Through the scientific combination of “beauty tablets plus collagen drink,” the product aims to deliver comprehensive nutrition and innovative collagen care. The company expects that promotional campaigns and new product exposure will help drive overall revenue performance.
In terms of market strategies, DR.WU SKINCARE will integrate existing resources in Taiwan by combining online and offline marketing strategies and strengthening operations of its proprietary e-commerce platform to maximize resource efficiency and enhance overall performance. Overseas, the company will continue to deepen its presence in Northeast Asia and Southeast Asia, while in China it will operate primarily as a product supplier and R&D consultant, actively expanding brand influence in international markets.
At the same time, DR.WU SKINCARE noted that on the product front, it will continue to focus on the development of facial skincare products while actively expanding into the health supplement market, addressing consumer demand for both beauty and health.
Resource: 達爾膚第3季EPS 2.47元 業外收益回升 帶動單季轉盈
